Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6437-6448

  Yoshitake, Yoshihiro ^a,b   Nakatsura, Tetsuya ^a   Monji, Mikio ^a   Senju, Satoru ^a   Matsuyoshi, Hidetake ^a   Tsukamoto, Hirotake ^a   Hosaka, Seiji ^a   Komori, Hiroyuki ^a   Fukuma, Daiki ^a,b   Ikuta, Yoshiaki ^a   Katagiri, Toyomasa ^c   Furukawa, Yoichi ^c   Ito, Hiromi ^b   Shinohara, Masanori ^b   Nakamura, Yusuke ^c   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A24 ANTIGEN; MESSENGER RNA; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; EPITHELIUM CELL; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; ANIMALS; ANTIGENS, NEOPLASM; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM, RESIDUAL; PLACENTA; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TESTIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 5144228047     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0841     Document Type: Article

References (50)

1. Tepper J. Refluxtions on esophageal cancer: can we swallow the changes? J Clin Oncol 2000;18:453-4.
2. Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol 2000;18:455-62.
3. Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A, Langlois-Zantin O. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg 1996;223:127-33.
4. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992;127:1446-50.
5. Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Huntingt.) 1994;8: 37-42; discussion 44-5, 50-2, 61.
6. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994;343:1122-6.
7. Ueda Y, Yamagishi H, Tanioka Y, et al. Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology 1999;46 Suppl 1:1274-9.
8. Nakao M, Yamana H, Imai Y, et al. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995;55:4248-52.
9. Toh U, Yamana H, Nakao M, et al. HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers. Cell Immunol 1997;177:137-43.
10. Azuma K, Shichijo S, Maeda Y, et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res 2003;63:854-8.
11. Maeda Y, Ito M, Harashima N, et al. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer 2002;99:409-17.
12. Ito M, Shichijo S, Tsuda N, et al. Molecular basis of T-cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001;61: 2038-46.
13. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-36.
14. Monji M, Senju S, Nakatsura T, et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun 2002;294:734-41.
15. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001;281:936-44.
16. Kihara C, Tsunoda T, Tanaka T, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001;61:6474-9.
17. Karaki S, Kariyone A, Kalo N, Kano K, Iwakura Y, Takiguchi M. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies. Immunogenetics 1993;37:139-42.
18. Yang D, Nakao M, Shichijo S, et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999;59:4056-63.
19. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
20. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10: 6612-21.
21. Monji M, Nakatsura T, Senju S, Yoshitake Y, et al. Identification of a novel cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. In press 2004.
22. Gomi S, Nakao M, Niiya F, et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999;163:4994-5004.
23. Masuda M, Senju S, Fujii S, et al. Identification and immunocytochemical analysis of DCNP1, a dendritic cell-associated nuclear protein. Biochem Biophys Res Commun 2002;290:1022-9.
24. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol 2004;172:776-86.
25. Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002;8:2626-31.
26. Katahira T, Nakamura H. Gene silencing in chick embryos with a vector-based small interfering RNA system. Dev Growth Differ 2003; 45:361-7.
27. Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V. Inducible, reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci USA 2004;101:1927-32.
28. Sakai Y, Saijo M, Coelho K, Kishino T, Niikawa N, Taya Y. cDNA sequence and chromosomal localization of a novel human protein, RBQ-1 (RBBP6), that binds to the retinoblastoma gene product. Genomics 1995;30:98-101.
29. Witte MM, Scott RE. The proliferation potential protein-related (P2P-R) gene with domains encoding heterogeneous nuclear ribonucle-oprotein association and Rb1 binding shows repressed expression during terminal differentiation. Proc Natl Acad Sci USA 1997;94:1212-7.
30. Gao S, Witte MM, Scott RE. P2P-R protein localizes to the nucleolus of interphase cells and the periphery of chromosomes in mitotic cells which show maximum P2P-R immunoreactivity. J Cell Physiol 2002;191:145-54.
31. Gao S, Scott RE. Stable overexpression of specific segments of the P2P-R protein in human MCF-7 cells promotes camptothecin-induced apoptosis. J Cell Physiol 2003;197:445-52.
32. Simons A, Melamed-Bessudo C, Wolkowicz R, et al. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene 1997;14:145-55.
33. Argentini M, Barboule N, Wasylyk B. The contribution of the RING finger domain of MDM2 to cell cycle progression. Oncogene 2000;19:3849-57.
34. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 2003;23: 4939-47.
35. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001;61:6555-62.
36. Zhang ZW, Patchett SE, Farthing MJ. Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity. Anticancer Drugs 2000;11:757-64.
37. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
38. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
39. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
40. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 1998;75:451-8.
41. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995;181:363-8.
42. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996;47:93-101.
43. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
44. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
45. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000;356:1163-5.
46. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
47. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999;94: 1201-8.
48. Toh U, Yamana H, Sueyoshi S, et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 2000;6:4663-73.
49. Toh U, Sudo T, Kido K, et al. Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer. Int J Clin Oncol 2002;7:372-5.
50. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001;22:516-23.